MedTrace Logo

GLP-1R Actions on Muscle and the Skeleton

NCT07154719 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-04-16

No results posted yet for this study

Summary

The GRAMS study objectives are to assess the musculoskeletal changes that occur after weight loss using GLP-1 based therapy. A lifestyle intervention with diet and exercise is included to assess any mitigating effects are provided, versus a control group with regular exercise and diet.

Conditions

Interventions

DRUG

Tirzepatide

GLP-1 based treatment for obesity

BEHAVIORAL

Lifestyle toolkit

2 ABBOTT protein shakes daily and resistance-based exercise x 3 days per week.

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Pennington Biomedical Research Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-09
Primary Completion
2026-12-01
Completion
2026-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07154719 on ClinicalTrials.gov